Anti-dementia drugs

1. Dementia is a disease that does not have the right way to treat it right now, so there is a high need for the development of a fundamental dementia treatment. Biopharma Research Centre, we are researching and developing new medicines for the treatment of dementia, which have completely different paradigm from those of existing dementia treatments, as well as new medicines that improved the treatment of existing dementia treatments.

   Anti-dementia drugs with improved therapeutic effect and convenience of taking medicine.

   We are researching and developing a dementia treatment medicine that improves convenience of taking medicine and compliance of taking medicine by applying the slow-released injectable technology developed through cooperation research development to new medicine.

   Dementia treatment medicine that can cure the fundamental factors of dementia.

   The existing dementia treatment was not able to cure the dementia fundamentally, but the BIOPHARMA RESEARCH CENTRE PHARMA has found two kinds of dementia treatment candidates which can be the fundamental treatment of dementia.

Major Antidepressant

A major antidepressant with a different route of administration compared to conventional products.

For those patients who are unable to administer major antidepressant medicines through the existing route of administration, they are developing improved new medicines that are modified by injections, which makes it easier to differentiate them from existing ones. In addition, the introduction of additional new patients will facilitate market expansion. Based on this fact, we are researching and developing a new treatment for dementia.

Anticancer Adjurvants

Renal toxicity by anticancer drugs

We are researching and developing adjuvants that are used as anticancer drugs as a component derived from natural materials that can reduce or inhibit adverse reactions such as renal toxicity caused by platinum-based anticancer drugs.

Liver and pulmonary fibrosis

Therapeutic agent for liver and pulmonary fibrosis caused by anticancer drugs

We are researching and developing adjuvants that are used as anticancer drugs as a component derived from natural materials that can reduce or suppress adverse reactions such as liver and pulmonary fibrosis caused by platinum-based anticancer drugs.

Other

Type 2 antidiabetic that greatly improves compliance of taking medicine for paitent.

It is a natural medicine for atopic dermatitis, which is low in toxicity compared to existing products.

Medicine of autoimmune disease, Crohn's disease.

A natural product derived from menopausal / postmenopausal, symptomatic treatment and prevention of disease. Natural remedies for menopausal / postmenopausal symptoms and for the prevention of disease.

The development of generic & new medicine.

• Tablet, capsule, Cream, Liquid for external use
• Research on various dosage form and commercialization Development of first generic medicine in specialized areas and development of new medicine (slow-release medicine, complex medicine).

New Medicine Research (Synthetic medicine, Natural medicine)

• New medicine development, non-clinical, clinical trial through industry-university cooperation and open innovation.
• manufacture of test medicine for clinical trials (Securing stability)
• Set new medicine specifications (Including raw materials, product standards and test method setting and permission data setting)

Analysis study

• Identification of Pharmaceutical Equivalence (Instrumental analysis and physicochemical analysis)
• Development of analytical methods for new product and new medicine development
• Product standards and test methods

Researching Infrastructure Technologies

• Study on emission control using "DDS (Drug Delivery System)".
• Studies on solubilization of poorly soluble materials. (Emulsion, Solid dispersion)
• Special formulations. (Oral Disintegration, Mini-Tablet)
• Formulation modification technology. (tableting of soft capsules and liquids)
• Shielding the taste of liquid and powder.
• Long acting Release (Depot)

Biopharma

Restoring Hope to People with Rare Diseases

Oncology, Immunology, and Cell Therapy

Biopharma achieved the development of drug to treat for neutropenia. Designed as a supplement for immunosuppressant chemotherapy, the drug effectively mitigates the side effects of the treatment. Additionally, it offers a longer half-life compared to its first-generation counterpart. This advancement has enabled the Indian medical community to discontinue importing similar drugs from overseas. Furthermore, Biopharma is working on introducing an innovative antibody production technology and will continue researching and developing new candidate materials for immunotherapy for cancer patients. Its specialized subsidiaries are also helping the company strengthen its position in cell therapy, which is emerging as a new potential source of economic growth.

Rare Disease Treatments

Biopharma, we believe it is our duty to research and develop treatments for rare diseases. Despite how difficult they are to make or how limited their market prospect is, they play a crucial role in saving lives. The first sign of success started in 2012 and came in the form of Hunterase, a treatment for Hunter syndrome, a hereditary metabolic disorder known as mucopolysaccharidosis (MPS) type-II. Developed as the second Hunter syndrome treatment globally, Hunterase has helped reduce the financial burden on patients and their families by replacing the more expensive imported alternative and significantly improving their quality of life, Biopharma's plan to bring this innovative drug

Biopharma We Open Up the Healthy Future

Future Strategy

Biopharma has been accumulating expertise in plasma derivatives, vaccines, and recombinant proteins. In the process, the company has made significant impact on treatment for patients and on public health. Biopharma is now ready to maximize and upgrade the values of its existing products, and engage in strategic R&D activities to further strengthen its pipeline of products against a wider range of diseases.